Chugai Of Japan Gets Gastric Cancer Indication For Xeloda Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Chugai Pharmaceutical said it has received clearance to market its Xeloda (capecitibine) for treating advanced or recurrent gastric cancer